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Antimicrobial peptides (AMPs) have received considerable interest as a source of new antibiotics with the potential for treatment of multiple-
drug resistant infections. An important class of AMPs is composed of linear, cationic peptides that form amphipathic α-helices. Among the most
potent of these are the cecropins and synthetic peptides that are hybrids of cecropin and the bee venom peptide, mellitin. Both cecropins and
cecropin-mellitin hybrids exist in solution as unstructured monomers, folding into predominantly α-helical structures upon membrane binding
with their long helical axis parallel to the bilayer surface. Studies using model membranes have shown that these peptides intercalate into the lipid
bilayer just below the level of the phospholipid glycerol backbone in a location that requires expansion of the outer leaflet of the bilayer, and
evidence from a variety of experimental approaches indicates that expansion and thinning of the bilayer are common characteristics during the
early stages of antimicrobial peptide–membrane interactions. Subsequent disruption of the membrane permeability barrier may occur by a variety
of mechanisms, leading ultimately to loss of cytoplasmic membrane integrity and cell death.
© 2006 Elsevier B.V. All rights reserved.Keywords: Antimicrobial peptide; Cecropin; Mellitin; Magainin; Spin label; EPR1. Introduction
The ever increasing prevalence of multiple-drug resistant
pathogens is a major health concern throughout the world. As of
2003, over 57% of Staphylococcus aureus infections in US
intensive care units were resistant to multiple antibiotics [1], and
there is an emerging resistance to vancomycin [2–4]—a drug
that has often been considered the last line of defense. Thus, the
need for the development of new antibiotics cannot be
overstated. During the past two decades a large number of
peptides with potent antibacterial, antiviral, and antifungal
properties have been identified from a wide range of both
vertebrate and invertebrate species. These antimicrobial pep-
tides (AMPs) form an essential part of the “innate” arm of host
resistance, serving as a first line of defense against infection.
Importantly, AMPs are believed to have a mechanism of action
entirely distinct from those of current clinically-used antibiotics,⁎ Corresponding author. Tel.: +1 414 456 4037; fax: +1 414 456 6512.
E-mail address: jfeix@mcw.edu (J.B. Feix).
0005-2736/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2006.02.021and so there is great interest in their development for treatment
of drug-resistant infections [5–8].
AMPs can be broadly classified based on secondary
structure and composition [5–7]. Ribosomally-synthesized
AMPs, containing only natural amino acids, may be grouped
into linear, α-helical peptides (such as cecropins, magainins,
and mellitin), peptides characterized by enrichment in one or
two amino acids (proline arginine-rich PR39, indolicidin), and
peptides containing disulfide bonds (e.g., defensins, prote-
grins). There are also a large number of peptides with potent
antimicrobial activity that are synthesized extra-ribosomally or
contain substantial post-translational modifications, for exam-
ple lipopeptides (polymyxin, dermaseptin) and the lantibiotics
[9], which contain non-native amino acids and/or non-peptide
backbone structures. In addition, a wide variety of synthetic
AMPs have been developed utilizing either a combinatorial
synthesis approach [10–12] or through modification of existing
AMPs [13]. These include peptides such as the potent
bactericidal–fungicidal decapeptide, KSL [12], the ornithine-
based lipopeptide MSI-843 [14], and cyclic peptides contain-
ing a combination of D- and L-amino acids [15–17].
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believed to be based on recognition of general properties of the
cell membrane. This is supported by a number of lines of
evidence, including the sequence diversity of AMPs and the fact
that synthetic, all D-amino acid analogs retain full functional
activity [18–20]. AMPs bind strongly to lipid bilayers and
binding is enhanced by increasing amounts of anionic lipids
[21–25]. AMPs dissipate transmembrane ionic gradients
[21,26–32], and release entrapped solutes from liposomes
[21,23,33,34]. Prokaryotic cell membranes have a much more
negative surface potential than eukaryotic membranes [25,35],
promoting electrostatic interactions with the cationic peptides
and providing at least a partial explanation for specificity.
Although studies have shown that some antimicrobial peptides
interact with intracellular targets [36–38], these peptides still
must traverse the cell membrane to reach their site of action.
Consequently, an understanding of peptide–membrane interac-
tions is essential for the improved design and development of
AMP antibiotics. In this review we will consider the membrane-
bound structure, peptide–membrane interactions, and mecha-
nism of action for the linear, amphipathic α-helical class of
AMPs, with particular emphasis on a group of peptides that are
synthetic hybrids of cecropins and mellitin.
2. Cecropins
Cecropins were among the first antibacterial peptides
identified. Initially isolated from the silk moth Hyalophora
cecropia [39–41], cecropin analogs have now been isolated
from a variety of insect species [13], and a mammalian (porcine)
version has also been found [42]. As a family, cecropins contain
31–39 amino acids with an amphipathic, basic N-terminal
domain and a hydrophobic C-terminal domain [43–45] (Table
1). Numerous synthetic analogs of the naturally-occurring
cecropins have been used to elucidate sequence–activity
relationships. Substitution of proline residues in the N-terminal
domain significantly decrease activity, indicating the impor-Table 1
Representative amino acid sequences of naturally-occurring cecropins
cecropin A: KWKLFKKIEK10 VGQNIRDGIIKAGP24
AVAVVGQATQIAK37CONH2
cecropin B: KWKVFKKIEK10 MGRNIRNGIVKAGP24
AIAVLGEAKAL35CONH2
cecropin D: WNPFKELEK9 VGQRVRDAVISAGP23
AVATVAQATALAK36CONH2
cecropin B1: RWKIFKKIEK10 MGRNIRDGIVKAGP24
AIEVLGSAKAI35CONH2
cecropin B2: WNPFKELER9 AGQRVRDAVTSAAP23
AVATVGQAAAIAR36CONH2
cecropin C: GW-LKKLGKR9 IERIGQHTRDATIQGLG26
IAQQAANVAATAR39CONH2
cecropin P1: SW-LSKTAKK9 LENSAKKRISEG21
IAIAIQGGPR31COOH
Cecropins A, B, and D are found inHyalophora sp. [39,41], cecropin B1 is from
Bombyx mori [13], cecropin B2 is from Manduca sexta [129], cecropin C from
D. melanogaster [13], and cecropin P1 is found in the intestinal mucosa of the
pig [42]. The cationic, amphipathic N-terminal domain is shown in italics, and
the predominantly hydrophobic C-terminal domain is underlined.tance of the amphipathic α-helix [43]. A conserved aromatic
residue at position 2 is essential for full antimicrobial activity,
with analogs containing the native tryptophan being more active
than those containing phenylalanine [43]. Studies using
modular constructs have indicated that a general organization
of an amphipathic N-terminal helix connected to a hydrophobic
C-terminal helix by a flexible hinge region is required for
strong, broad-spectrum antimicrobial activity [45]. These
studies led to the synthesis of a chimeric cecropin A–cecropin
D construct with enhanced activity [44].
Cecropins posses broad antibacterial activity against essen-
tially all Gram-negative bacteria and some Gram-positive
bacteria [43–45], but notably are relatively inactive against
Staphylococcus aureus [46–48]. Cecropins also show good
activity against the protozoan parasite, Leishmania [49], the
yeast Candida albicans [50], and the malarial parasite
Plasmodium falciparum [47]. Transgenic higher plants engi-
neered to express cecropins have been developed to enhance
resistance against bacterial and fungal phytopathogens [51].
Cecropins have also shown selective activity in vitro against a
number of tumor cell lines [52,53]. Cecropins exhibit low
toxicity toward normal eukaryotic cells and relatively weak
hemolytic activity [46–48]. In a rat model of Gram-negative
bacterial sepsis, treatment with cecropin B alone or in
combination with β-lactams significantly reduced plasma levels
of tumor necrosis factor-α (TNF-α) and endotoxin (measures of
septic shock), decreased infectious load, and improved survival
[54].
Circular dichroism (CD) studies show that cecropins are
unstructured in aqueous solution, but form a high percentage of
α-helical secondary structure in the presence of hexafluoroiso-
propanol (HFIP) [43,55], vesicles of lipopolysaccharide (LPS)
[56], SDS micelles [57], or liposomes [57]. Synthetic all-D
enantiomers have been shown to form left-handed helices with
mirror-image CD spectra, are protease resistant, and to have the
same level and range of antibacterial activities as the naturally
occurring L-enantiomers [18,33,56]. Solution NMR studies of
cecropin A in 15% HFIP indicated the presence of two well-
defined helices, encompassing residues 5–21 and residues 24–
37 and corresponding to the cationic N-terminal and hydro-
phobic C-terminal domains, respectively [58]. The two helices
were oriented at an angle of 70–100°, consistent with the
presence of a Gly23–Pro24 hinge. Solution-phase NMR of
cecropin P1 in 30% HFIP also indicated adoption of helical
secondary structure, in this case a single α-helix spanning
almost the full length of the peptide [59].
3. Mellitin
Mellitin, a 26-residue peptide found in the venom of the
honey bee Apis mellifera, also contains distinct hydrophilic and
hydrophobic domains but in reverse order relative to cecropins,
with four cationic amino acids sequestered near the C-terminus
(Table 2). Mellitin displays strong, broad-spectrum antimicro-
bial activity, but is also highly hemolytic [46,47]. In solution,
mellitin undergoes a concentration-dependent equilibrium
between random-coil monomer and a predominantly α-helical
Table 2
Amino acid sequences of cecropin A, mellitin, and cecropin-mellitin hybrid peptides first identified by Andreau et al. [46]
The cecropin-mellitin hybrids incorporate the cationic N-terminal domain of cecropin A (red box) and mostly hydrophobic amino acids from the N-terminal of
mellitin (blue box).
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of bilayers mellitin forms N-terminal and C-terminal α-helices
separated by a flexible hinge (reviewed in 61, 62). At high lipid:
peptide ratios (e.g., >200:1) membrane-bound mellitin is
monomeric with its helical axis parallel to the membrane
surface [61,62], with each of its lysine residues exposed to the
aqueous phase [63]. As the concentration of membrane-bound
mellitin is increased, the peptide undergoes a dynamic
reorientation relative to the membrane normal and eventually
produces a complete destruction (micellization) of the mem-
brane bilayer [61,62].
4. Cecropin-mellitin hybrids
In order to reduce the size of full-length cecropins to
facilitate their solid-phase synthesis, Bowman, Merrifield, and
co-workers synthesized and evaluated the antimicrobial activity
of a large group of peptides that were hybrids of cecropin A and
mellitin. These chimeric peptides were constructed from various
combinations of the hydrophilic domain of cecropin with the
hydrophobic domain of mellitin, or vice versa. Initial studies
examined peptides containing from 18 to 37 amino acids, with
net charges of +5 to +7 [47,48]. Many of these constructs
displayed antibacterial activity comparable to full-length
cecropins, and yet lacked the hemolytic properties associated
with mellitin. Interestingly, and in contrast to full-length
cecropins, several of the hybrids displayed good antibacterial
activity against Gram-positive organisms, including Staphylo-
coccus aureus [46–48]. Those studies were followed by a
further reduction in size, with the identification of several active
constructs having only 15 amino acids [46]. These minimal
peptides all contain the first 7–8 residues of cecropin A with
various combinations of mostly hydrophobic amino acids from
near the N-terminus of mellitin (Table 2). Lethal concentrations
against a panel of bacteria ranged from 0.1 to 15 μM, while
hemolytic concentrations were >300 μM [46].
Hancock and co-workers have carried out extensive studies
on a cecropin-mellitin (CM) hybrid consisting of the first
8 residues of cecropin A and the first 18 residues of mellitin, C
(1–8)M(1–18), which they designate CEME [64–66]. This
construct demonstrates strong antimicrobial activity against
both Gram-negative and Gram-positive bacteria [65–68].
CEME has demonstrated high affinity for lipopolysaccharide
(LPS), and enhances both outer and cytoplasmic membrane
permeability [65, 67]. CEME and an analog with two additionalcationic residues near the C-terminus also inhibited LPS-
induced TNF-α production by isolated macrophages, and
improved survival in a murine model of acute septic shock
[69]. These peptides also bind lipoteichoic acid, a cell-wall
component of Gram-positive bacteria, and were able to reduce a
number of physiological effects (e.g., TNF-α and cytokine
production) related to Gram-positive sepsis [70].
An even smaller CM hybrid consisting of the first seven
residues of cecropin A and residues 2–9 of mellitin, C(1–7)M
(2–9) (which we designate CM15, Table 2) has also received
particular attention due to its broad-spectrum antimicrobial
efficacy [46]. Both CM15 and CEME have been shown to be
active against the protozoan parasite Leishmania [49].
Activity of CM15 against Leishmania is enhanced by N-
terminal substitution with fatty acids up to 12 carbons, but
acylation of the Lysine 7 ε-amino group significantly reduced
both bactericidal and leishmanicidal activities [49]. The N-
octanoyl derivative of CM15 has been shown to be safe and
effective in treatment of naturally-acquired canine leshmania-
sis [71].
As with cecropin A [18], the all-D enantiomer of CM15
retains full biological activity against a broad panel of bacterial
species [20], indicating that interaction with cellular targets
occurs in a non-stereospecific manner. Interestingly, the reverse
(“retro”) and all-D reverse (“retroenantio”) sequences were
active against some bacterial strains (e.g., E. coli, Bacillus
subtilis, Streptococcus pyogenes), but inactive against either S.
aureus or Pseudomonas aeruginosa [20]. Thus it consistently
appears that chirality is not a factor in determining peptide
efficacy, although in some cases it may be important to consider
sequence order and the direction of amide bonds.
CM hybrids, like their parent peptides, are members of the
linear, amphipathic α-helical class of AMPs. CM hybrids exist
in a random coil configuration in solution, and only adopt their
α-helical secondary structure in the presence of membranes or
helix-promoting organic solvents [46]. Solution NMR of a 26-
residue CM hybrid, C(1–13)M(1–13), in 30% HFIP indicated
the formation of two α-helices separated by a flexible linker
[72], similar to the structural motif found for cecropin A. A
predominantly α-helical solution NMR structure has also been
reported for C(1–8)M(1–12) in 50% HFIP [73].
Upon folding, CM hybrids are highly amphipathic, with an
almost ideal distribution of polar and non-polar amino acids
(Fig. 1). CM hybrids retain the domain structure of full-length
cecropins, with a strongly cationic N-terminal domain and a
Fig. 2. Association of amphipathic α-helical peptides (cylinders) with a lipid
bilayer can occur in three general orientations: parallel to the membrane surface,
at an oblique angle, or perpendicular to the membrane surface (i.e., along the
bilayer normal).
Fig. 1. Helical wheel display of the cecropin-mellitin hybrid, CM15. (A) Full sequence, (B) representation with the omission of Lys1–Trp2. It has been suggested that
the first two amino acids may not be included in the α-helical secondary structure. Note that, in either case, the polar and non-polar side chains are sequestered on
opposite faces of the helix.
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hybrids also contain a centrally-located glycine, similar to the
gly-pro hinge that has been shown to be functionally important
in full-length cecropins [45]. However this glycine does not
appear to be a required for antimicrobial activity in CM hybrids
since it is absent in a number of effective analogs [46]. Indeed,
the 15-residue C(1–7)M(3–10) construct, in which isoleucine
8 is replaced by glycine, exhibits significantly diminished
antibacterial activity [74]. Substitution of Ile8 with serine also
strongly reduced activity, suggesting the requirement of a
hydrophobic amino acid at this position [74]. When folded into
a membrane-bound α-helix, Ile8 is buried deeply in the bilayer
(discussed below), and so substitution of a polar amino acid at
this site may prevent membrane insertion. Decreasing the length
of CM15 by one residue to give the 14-mer, C(1–7)M(2–8),
reduced its antibacterial activity, while adding an additional
residue, giving C(1–7)M(2–10), slightly enhanced activity
[74].
5. Peptide–membrane interactions
Despite extensive study, the precise mechanisms of peptide–
membrane interaction and cell killing have not been firmly
established for many antimicrobial peptides. It is generally
agreed that, upon addition to a bacterial cell suspension, AMPs
undergo “self-promoted uptake” to cross the outer membrane or
cell wall [64,67], followed by disruption of the cytoplasmic
membrane as the lethal event leading to bacterial cell death
[30,32,75]. It is proposed that the initial binding of AMPs to the
outer membrane displaces divalent cations, destabilizing the cell
envelope and resulting in the subsequent uptake of the peptide
[64]. Several studies have shown that the magainins [32] and
CM hybrids [65] disrupt the outer membrane permeability
barrier. Although the molecular mechanisms involved in
crossing the outer membrane remain poorly defined at a
molecular level, most studies have focused on the events
associated with binding to and disruption of the cytoplasmic
membrane. This may occur through a detergent-like “carpet”
mechanism [29,33,76], or the formation of discrete pores that
dissipate ion gradients [74,75,77].It can be imagined that the initial association of an α-helical
AMP with a lipid bilayer could occur in any of three general
orientations: parallel to the membrane surface, along the
membrane normal, or at an oblique angle (Fig. 2). There are
precedents in the literature for all three cases. Peptides based on
the myristoylated alanine-rich C-kinase substrate (MARKS) for
protein kinase C [78] and model peptides composed entirely of
lysine and phenylalanine [79] bind parallel to the membrane
surface with varying depths of penetration depending on overall
hydrophobicity. Peptides designed to model transmembrane
helices [80], transmembrane helices of integral membrane
proteins, and certain peptide ionophores such as alamethicin
[81] align more or less vertically across the bilayer; while the
membrane-insertion sequences of SNARE proteins [82,83] and
viral fusion peptides [84,85] integrate into the bilayer at an
oblique angle.
Both full-length cecropins and CM hybrids appear to be
monomeric in solution. Using a spin-labeled analog of cecropin
AD we found no evidence of aggregation in either physiological
or low ionic strength solutions up to a peptide concentration of
200 μM [22,86]. Although aggregation of cecropin AD was
observed upon addition of low concentrations (5–10%) of
HFIP, upon titration with higher HFIP concentrations the
peptide reverted to a folded monomer—consistent with a model
in which peptide binding and secondary structure formation are
a concerted process [86]. Sedimentation equilibrium studies
indicate that cecropin A is also monomeric in solution [21].
Thus, the initial event in peptide–membrane interaction is the
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phospholipid. This is a situation that can be readily modeled
using artificial membrane bilayers.
Solid-state NMR of full-length cecropin A selectively 15N-
labeled at either Val11 or Ala27 and incorporated into oriented
planar bilayers indicated that the amide bonds at these two sites
were oriented parallel to the membrane surface [87], inferring
that both the N- and C-terminal helical domains lie along the
surface of the bilayer. Consistent with these results, Silvestro
and Axelson used internal reflection Fourier-transform infrared
(FTIR) spectroscopy to demonstrate that upon initial membrane
association cecropin A adopted secondary structure that was
primarily α-helical, with the longitudinal helical axis preferen-
tially oriented parallel to the membrane surface [88]. The
peptide expanded the membrane surface upon insertion, but did
not alter its structure or orientation. Attenuated total reflection
(ATR)-FTIR studies indicate that cecropin P1 also orients
almost parallel to the membrane surface upon initial binding to
PE (phosphatidylethanolamine)–PG (phosphatidylglycerol)
membranes that mimic the Gram-negative bacterial inner
membrane [89]. Similarly, numerous studies have indicated
that members of the magainin family of peptides initially bind to
membranes with their long helical axis parallel to the bilayer
surface [61,62]. We have used site-directed spin labeling
(SDSL) to characterize the initial interaction of CM15 with
liposomes that mimic the bacterial inner membrane [24]. In the
SDSL approach, peptides are synthesized or expressed with a
single cysteine residue at any given desired location (or,
typically, at all possible locations, Fig. 3). The cysteine residue
is then covalently modified with a sulfhydryl-specific nitroxide
spin label (Fig. 4), allowing study of the peptide structure and
dynamics by electron paramagnetic resonance (EPR) spectros-
copy. One advantage of SDSL relative to other molecular probe
techniques is that the labeled side chain is relatively small –Fig. 3. Single-cysteine analogs of CM15 used for the selective attachment of
spin labels or other sulfhydryl-specific probes. In this study the N- and C-termini
were avoided since they are typically unstructured. The tryptophan at position 2
was also retained throughout, both because it is highly conserved (see Table 1)
and as a chromophore for quantitation of peptide concentration.about the same molecular volume as tryptophan (Fig. 4) – so
that the physical properties of the peptide are not significantly
perturbed. Additionally, EPR is unaffected by the optical
properties of the sample so that one can conduct studies across a
wide range of lipid concentrations without concern for light-
scattering or inner filter effects. SDSL provides access to two
particularly important parameters: the rotational dynamics of
the labeled side chain, which is sensitive to local structure and
intermolecular interactions, and the accessibility of the
nitroxide—which can be used to determine the depth of the
labeled site in a lipid bilayer (for reviews of SDSL methods and
applications, see references 90,91).
To characterize the structure and localization of membrane-
bound CM15, we carried out a “nitroxide-scanning” study using
several of the single-cysteine analogs shown in Fig. 3 [24].
These peptides were spin-labeled and mixed with large
unilamellar vesicles (LUVs) composed of E. coli inner
membrane lipids at a high lipid:peptide ratio, designed to
mimic conditions of initial peptide binding. The resulting EPR
spectra indicated that under these conditions the peptides adopt
a folded conformation and are fully membrane-bound [24].
Bilayer depth was determined for each spin-labeled analog,
giving the sequence-related pattern shown in Fig. 5. As can be
seen, the experimental data fit well to an idealized α-helix with
3.6 residues/turn. This is in agreement with CD results showing
that CM15 is essentially 100% α-helical in the presence of
liposomes (Fig. 6). In addition, the data in Fig. 5 show that all of
the residues along the hydrophobic face of the peptide (i.e., F5,
I8, L12) reside at approximately the same depth—about 12.5 Å
below the bilayer surface, while all of the side chains along the
hydrophilic face lie about 2.5 Å above the membrane. This
pattern clearly indicates that upon initial binding CM15
intercalates parallel to the membrane surface, with its central
helical axis at a depth of ∼5 Å (Fig. 7). Such localization is
well-suited to bury non-polar side chains in the hydrophobic
core of the membrane, while positioning lysine residues to
interact with lipid phosphates. Importantly, essentially the entire
molecular volume of the peptide must be accommodated by the
membrane, which may be an important factor in promoting
destabilization and eventual disruption of the bilayer.
6. Mechanisms of membrane disruption
Mechanisms of membrane disruption by AMPs have been
intensely studied. In general, membrane disruption is believed
to occur either via a detergent-like carpet mechanism [33,76,
89], through induction of non-lamellar lipid phases [92], or
through formation of discrete pores [77]. There is good
experimental evidence for each of these processes, and it may
be that different peptides utilize different mechanisms to
ultimately disrupt the microbial membrane. These mechanisms
also need not be mutually exclusive, one process may represent
an initial or intermediate step and another may be its
consequence. Additional factors such as lipid-to-peptide ratio
and target membrane composition may also be involved.
Many studies of membrane disruption by AMPs have
utilized model membranes (lipid monolayers, liposomes,
Fig. 4. Cysteine labeling with the methiosulfonate spin label, MTSL. Note that the nitroxide side chain has about the same molecular volume as tryptophan.
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as discussed above is a key target of AMPs. The use of model
membranes allows rigorous control and experimental manip-
ulation of membrane composition and lipid–peptide ratio. Upon
the addition of AMPs to these artificial membranes, AMP
monomers bind to the outer leaflet of the phospholipid bilayer
as a first step in the processes of membrane lysis. As discussed
above, in the presence of a large excess of lipid (i.e., at a low
peptide/lipid ratio) the initial binding state of most α-helical
AMPs is parallel to the lipid bilayer surface. For example,
CM15 [24], cecropin A [87,88], cecropin P1 [89], and magainin
[93,94] all form their initial association with the membrane in
this fashion. It has been suggested that such binding induces
positive membrane curvature [92, 95], increasing the surface
area of the outer leaflet, leading to a decrease in the thickness of
hydrophobic core [77] and thinning of the lipid bilayer [96–
100]. An NMR study of a magainin analog, MSI-78,
demonstrated that peptide binding to the bilayer surface
disorders phospholipid acyl chains, which may be either a
cause or a reflection of bilayer thinning [98]. AMP concentra-
tion-dependent membrane thinning (proportional to the peptide/Fig. 5. Bilayer depth as a function of sequence position for membrane-bound
CM15, determined using SDSL. Single-cysteine analogs of CM15 were spin
labeled with MTSL and added to large unilamellar vesicles composed of E. coli
inner membrane lipids (PE:PG:CL, molar ratio 68:26:6) at a lipid:peptide ratio
of 200:1. The position determined is that of the spin labeled side chain relative to
the bilayer surface. Squares represent experimental data and the solid line is a
sine function with a periodicity of 3.6, characteristic of an idealized α-helix.
Some of the data were published previously [24].lipid ratio) has also been detected by X-ray diffraction [97,99].
Although the initial association of amphipathic α-helical AMPs
with the membrane surface increases the volume and surface
area of the outer leaflet, the inner leaflet is little affected and this
mismatch may contribute to peptide insertion and/or aggrega-
tion [88]. Thus, changes in the physical properties of the lipid
bilayer induced via peptide binding appear to facilitate further
penetration of AMPs, which in turn may lead to the formation of
transmembrane pores.
A pore formation model of AMP activity was first suggested
by Baumann and Mueller based on their studies of alamethicin
[101]. Huang and coworkers have subsequently developed a
two-state model for membrane pore formation by α-helical
AMPs [77]. In this model, AMPs initially associate parallel to
the bilayer surface; when the peptide concentration reaches a
critical threshold, membrane-bound AMPs reorient and pene-
trate or insert into the hydrophobic core of bilayer with the
formation of transmembrane pores [77]. Evidence for this
general mechanism has come largely from studies that employ
oriented CD [99,102], as well as neutron [100–104] and X-ray
scattering [97,99,105,106]. Pore formation mechanisms are also
supported by studies showing the differential leakage of solutes
of different sizes and patch-clamp experiments demonstratingFig. 6. Circular dichroism spectra of CM15 in aqueous solution (dotted line) and
in the presence of PE:PG (8:2 molar ratio) unilamellar vesicles. Analysis of the
spectrum in the presence of liposomes using the K2D algorithm [130] indicates
nearly 100% α-helical secondary structure.
Fig. 7. Localization of membrane-bound CM15. This model is based on SDSL
data obtained at a lipid:peptide ratio of 200:1. The peptide forms a single,
uninterrupted α-helix with its helical axis parallel to the membrane surface
approximately 5 Å below the aqueous interface (defined as the level of the
phospholipid glycerol backbone). This positioning buries non-polar side chains
in the hydrophobic core of the bilayer and allows lysine residue on the polar face
of the helix to hydrogen bond and/or salt bridge with the lipid head groups.
Incorporation of the peptide at this location would require expansion of the outer
leaflet of the bilayer.
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dissipates membrane potentials at concentrations much lower
than those required for release of calcein [21], and Christensen
et al. found that cecropin A and its analogues formed time-
variant, voltage-dependent ion channels in planar lipid mem-
branes [75]. Ion channel formation with discrete open and
closed states has also been demonstrated for CM15, where a
correlation between channel activity, pore size, and peptide
concentration was observed with larger pores being formed at
higher peptide concentration [74].
Two distinct channel architectures have been described: a
barrel-stave structure that involves the formation of transmem-
brane ion channels, and a torroidal-pore model in which theFig. 8. Models of transmembrane channel formation. (A) Peptide α-helices (cylinders
embedded just below the aqueous interface. (B) Peptides continue to accumulate a
thinning. This step may or may not involve peptide–peptide aggregation. Once a critic
barrel-stave type pore, or (D) induce the localized formation of toroidal pores.transmembrane channel is composed of both AMPs and
membrane lipids [77] (Fig. 8).
6.1. “Barrel stave” model
Many investigators have suggested that certain AMPs self-
associate to form a transmembrane pore [26,74,75,102,107–
109]. The pore acts as a conductance channel that disrupts
transmembrane potential and ion gradients, leading to a leakage
of cell components and cell death. Dissipating the transmem-
brane electrochemical gradient causes a loss of the bacterial
cell's ability to synthesize ATP, and the increase in water and ion
flow that accompanies loss of the permeability barrier leads to
cell swelling and osmolysis. In the barrel-stave model,
amphipathic peptides align with their hydrophobic sides facing
the phospholipid acyl chains and their hydrophilic surfaces
lining a water-filled channel, much like the staves of a barrel
(Fig. 8). This model requires peptides to be sufficiently long to
traverse the hydrophobic core of the bilayer, and implies direct
contact between peptides upon channel formation.
A prototype for the formation of barrel-stave channels is the
fungal peptide, alamethicin. This 20-residue, hydrophobic
peptide from the fungus Trichoderma veridae contains eight
residues of the unusual amino acid α-methylalanine (α-
aminoisobutyric acid). Although alamethicin has little selectiv-
ity for bacterial or eukaryotic membranes, it has been intensely
studied due to its formation of voltage-gated channels in bilayer
systems [110–112]. In contrast to amphipathic peptides,
alamethicin monomers insert into the bilayer and then aggregate
in the membrane to form a barrel-stave pore [77]. Membrane
insertion of alamethicin was well established using oriented
circular dichroism and the change in peptide orientation was
observed reversibly and continuously [96]. An in-plane neutron) initially associate parallel to the membrane surface, either superficially (left) or
t or near the bilayer surface, disrupting lipid packing and causing membrane
al peptide/lipid ratio is reached, peptides either (C) insert into the membrane as a
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aqueous pores at high peptide concentration, based on the
difference in the scattering lengths of H2O and D2O [100]. This
neutron scattering study suggested a barrel-stave model of the
alamethicin channel with 8 or 9 monomer α-helices per channel
and a pore diameter of ∼18–26 Å, depending of lipid
composition and degree of hydration [96,104,113]. This is in
good agreement with studies on black lipid membranes, which
indicate 8–10 monomers per channel [101].
6.2. “Torroidal-pore” model
In this model, AMP-induced expansion of the lipid head
group region results in a bending of the bilayer back on itself
followed by connection of the outer and inner leaflets, and the
pore is composed of both peptide and phospholipid
[77,92,102,114,115] (Fig. 8). Positive curvature of the membrane
surface, resulting from accumulation of AMP at the bilayer
interface, facilitates the bending of phospholipids and toroidal
pore formation [92,95]. The energetically-favorable insertion of
peptide into the membrane may also produce changes in the
bilayer structure and facilitate toroidal pore formation [115].
The toroidal model was first proposed based on studies with
magainin peptides [115,116]. Magainin is a cationic amphi-
pathic α-helical peptide that forms transient ion channels [116].
The magainin pore size has been estimated at approximately 30
to 50 Å, formed with 4–7 peptides and 90 phospholipids per
pore [77,95,102,115]. 31P-NMR and differential scanning
calorimetry studies of MSI-78, an optimized, synthetic analog
of magainin, also support toroidal pore formation [92]. Recent
oriented CD and neutron scattering studies of melittin have
suggested that it also forms a toroidal-pore type channel, with a
pore diameter of ∼44 Å [102]. The size of pores induced by
melittin were estimated at around 25–30 Å in diameter based on
the release of differential sizes of fluorescence-labeled dextran
markers [117], which agrees well with the pore size (20–30 Å)
detected by osmotic protection of erythrocytes [118]. The
differences in these estimates are not unreasonable, given the
disparity in experimental methods, peptide/lipid ratios, and
degrees of hydration.
The structure of the toroidal pore model addresses the fact
that many AMPs are simply too small to span an unperturbed
phospholipid bilayer in an α-helical conformation. For an alpha-
helix,∼22 amino acids are required to transverse the bilayer, the
width of which is typically 32–38Å [35,100,119]. This is clearly
beyond the limits of CM15 and many other AMPs. For example,
the crystal structure of trichogin indicated that the length of α-
helix is ∼16 Å [120]. In the toroidal pore model, channels are
composed of a mixture of peptides and lipids and thus are not
required to span the complete bilayer. Toroidal pores are
proposed to form subsequent to peptide-induced membrane
thinning [77,97,99,105], which may also allow the penetration
of short peptides to form a peptide/lipid pore.
6.2.1. Pore formation and osmotic stress
Regardless of the precise channel structure, once even a
transient pore is formed across the membrane osmotic gradientswill induce cell swelling and thus facilitate further thinning of
the lipid bilayer. Hypo-osmotic conditions were shown to
enhance melittin-induced lysis even though the binding of the
peptide was not affected [121]. Interestingly, in lipid vesicles a
low concentration of cecropin A was able to dissipate ion
gradients across the membrane, while a higher peptide
concentration was required to release an encapsulated fluores-
cent marker—indicating that the mechanism of membrane
disruption may change with peptide/lipid ratio [21]. Low
concentrations of cecropin A dissipate the inner membrane
potential and kill E. coli cells, while much higher concentrations
are required to release β-galactosidase [21,30]. Similarly,
magainin 2a and its analogs induce a rapid release of intracellular
potassium at peptide concentrations that are cytotoxic, without
the release of intracellular β-galactosidase [32]. These data
suggest that prior to frank cytolysis, channel formation byAMPs
disrupts membrane potential and pH gradients. This in turn will
uncouple ATP synthesis and generate an osmotic shock.
Osmotic swelling can increase cell surface area by 5 to 25%
[122,123] and increases lipid alkyl chain disorder [121], which
may promote peptide interaction with the hydrophobic core of
the bilayer [121]. This may be particularly important for
phospholipids with a small head group (e.g. PE), and many
studies have demonstrated that membrane lipid composition has
an important influence on AMP interactions that extends
beyond simple electrostatic effects [25,109,124,125,126]. Such
changes in the physical properties of the membrane may also
enhance peptide binding—creating a disruptive cycle that
eventually leads to cell lysis. It is noteworthy that, because of
the rigidity of the cell wall, Gram-positive bacteria are able to
withstand turgor pressures 3 to 25 times higher than those
tolerated by Gram-negative bacteria [127] and this (along with
other influences of cell wall composition) may be one of the
reasons Gram-positive bacteria are typically more resistant to
antimicrobial peptides.
6.3. Detergent-like “carpet” mechanism
A conceptually different model for the way in which
AMPs disrupt membranes is the carpet mechanism (Fig. 9).
In this model, peptides accumulate at the bilayer surface like
a carpet and, above a threshold concentration of monomers,
the membrane is permeated and disintegrated in a detergent-
like manner without the formation of discrete channels
[7,29,33,76,89]. This mechanism was first proposed by Steiner
et al. based on the observation that, at the concentration needed
to obtain 50% cell killing, cecropin A was present in sufficient
amounts to completely cover the bacterial cell surface [33].
Subsequent studies on the porcine cecropin P1 were also
interpreted in terms of a carpet mechanism [29]. Cecropin P1
studies using ATR-FTIR spectroscopy indicated that it
incorporated parallel to the surface of the PE/PG membrane
and did not change the order parameters of the acyl chains,
suggesting the peptide did not translocate into the hydrocarbon
core [89].
In some instances, it can be quite difficult to distinguish
between carpet and toroidal pore mechanisms. For example,
Fig. 9. Model of membrane disruption by the carpet mechanism. As in channel formation, peptide α-helices (cylinders) initially (A) bind and (B) accumulate in an
orientation parallel to the membrane surface. (C) Continued accumulation of membrane-bound peptide associated with the phospholipid head-groups, eventually
covering (i.e., carpeting) the bilayer. (D) Detergent-like membrane disintegration.
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surface as a tightly-bound α-helix that does not reorient
along the bilayer normal (as occurs during toroidal pore
formation by mellitin and magainin, discussed above), even
at relatively high peptide/lipid ratios [128]. However, 31P-
NMR shows no evidence of an isotropic lipid component as
would be required in some stage of the carpet mechanism
[128].
Although the carpet and channel-forming models have a
number of differences, they also share some common
characteristics. Both types of mechanisms begin with AMP
association parallel to the membrane surface, followed by
peptide accumulation to some critical concentration. In the
carpet model, peptides remain associated with the phospho-
lipid head groups throughout the membrane disintegration
process [76]. This is similar to the transition that occurs in the
toroidal-pore model, and it has been suggested that the
formation of “holes” or toroidal pores may occur as an early
step in membrane disintegration, i.e. toroidal pores are
regarded as an intermediate state prior to micellization
[29,76]. It seems likely that most AMPs, by virtue of their
amphipathic character, will act as detergents at sufficiently
high concentrations. Nonetheless, in many cases (e.g.,
magainin, MSI-78) it is clear that pore formation is sufficient
to induce membrane lysis, without progression to complete
membrane destruction.
7. Conclusions
The intensive study of antimicrobial peptide–membrane
interactions has given rise to molecular models of membrane
disruption that include both the formation of discretechannels and more non-specific detergent-like processes.
Although there continues to be a debate regarding the
particular mechanism used by a given peptide, some general
principles are beginning to emerge. There is a general
consensus that, at least for the amphipathic α-helical class of
AMPs, peptides initially associate parallel to the bilayer
surface. There is also general agreement that for most
peptides this orientation persists until enough peptide
accumulates to achieve a critical membrane-bound concen-
tration. Peptide accumulation leads to a thinning of the
bilayer, which in turn leads to conditions allowing a localized
collapse of the lipid bilayer to form a lipid–peptide toroidal
pore, peptide self-association and insertion into the bilayer in
a barrel-stave arrangement, or simply a detergent-like
disintegration of the bilayer structure. The precise mechanism
almost certainly depends on the particular AMP involved,
and likely on the composition and physical properties of the
target bilayer as well. Peptide accumulation in the outer
leaflet of the bilayer is a critical phase in the process of
membrane disruption, and for many peptides it is becoming
increasingly clear that perturbation of the membrane near the
hydrophobic–hydrophilic interface leads to a thinning of the
lipid bilayer that precedes loss of the permeability barrier.
Further advances in our understanding of the molecular
events that lead to membrane disruption will facilitate
improvements in peptide design, and aid in the development
of new antibiotics based on AMP structures and mechanistic
principles.
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